The FDA has warned Sanofi about a series of “significant” manufacturing problems, including contamination, at a key facility in Massachusetts.

The FDA issued a warning letter to Sanofi regarding significant manufacturing violations at its Genzyme Corporation Facility in Framingham, Mass. The letter, dated Dec. 16, 2024, and amended Jan. 15, 2025, follows an inspection conducted from June 12 to July 9, 2024, and outlines multiple manufacturing violations for pharmaceuticals.

The U.S. Food and Drug Administration has warned the pharmaceutical company Sanofi about significant deviations from Current Good Manufacturing Practice for active pharmaceutical ingredients at their Genzyme manufacturing plant in Framingham,

Good morning! Here are the five things you need to know in local business news to start your busy — and still very cold — Thursday, including James Beard awards, an FDA warning, Big Lots for sale, GE Vernova's success and giant pink men without pants.

Despite receiving a prior wrist slap from the FDA in the shape of a Form 483, Sanofi is still working to right the ship at a U.S. | The FDA has slapped a warning letter on Sanofi’s Genzyme facility in Framingham,

Sisitsky submitted his plan to comply with the law late last month after city councilors voted to table discussing the issue until February.

Todd surrendered to police in Framingham after he was indicted on Thursday and was arraigned on Friday in Middlesex Superior Court in Woburn.